• Home
  •  / ProtoKinetix

ProtoKinetix

OverviewSuggest Edit

ProtoKinetix is a bio-technology company that provides medical researchers with a platform for enhancing cell survival and health, both in vitro and in vivo. At the heart of its technology is its patented anti-aging glycopeptide AAGP. This small molecule (580 Daltons) displays abilities in resolving challenges confronting medical researchers in such areas as regenerative medicine and as a therapy for diseases relating to tissue inflammation and oxidation stress. Because of its stability, small size and molecular makeup, it maintains its function in vivo without triggering the body's immune system. Further, it can function without toxic side effects common in treatments involving larger and less stable compounds.

TypePublic
Founded1999
HQMarietta, OH, USMap
Websiteprotokinetix.com

Recent NewsAll News

Latest Updates

Revenue (FY, 2014)$0
Share Price (Jun 2021)$0.1(-6%)
Cybersecurity ratingAMore

Key People/Management at ProtoKinetix

Clarence E. Smith

Clarence E. Smith

Chairman, President, Director
Edward P. McDonough

Edward P. McDonough

Director
Michael R. Guzzetta

Michael R. Guzzetta

Chief Financial Officer
Julia Levy

Julia Levy

Chairman, Business and Scientific Advisory Board
Show more

ProtoKinetix Office Locations

ProtoKinetix has an office in Marietta
Marietta, OH, US (HQ)
412 Mulberry St
Show all (1)

ProtoKinetix Financials and Metrics

ProtoKinetix Revenue

USD

Net income (Q1, 2021)

(133.1k)

Market capitalization (4-Jun-2021)

40.5m

Closing stock price (4-Jun-2021)

0.1

Cash (31-Mar-2021)

250.4k
ProtoKinetix's current market capitalization is $40.5 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

General and administrative expense

201.0k119.4k95.8k141.5k126.8k99.6k105.3k78.1k280.4k209.0k

R&D expense

117.4k74.5k13.8k158.9k450.9k296.5k337.1k369.5k527.3k

Operating expense total

318.4k119.4k170.3k155.3k285.7k550.5k401.8k415.1k650.0k736.3k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

General and administrative expense

44.3k28.6k34.4k28.7k29.6k20.9k26.0k23.3k14.1k49.0k21.0k38.9k42.7k23.2k21.4k29.5k17.3k32.1k29.8k12.5k17.4k25.6k13.7k33.9k91.4k76.9k57.0k71.0k46.5k41.0k

R&D expense

13.4k18.3k18.3k18.3k12.9k2.1k53.0k19.1k29.9k71.7k108.5k175.0k69.0k86.2k72.9k84.6k70.5k92.8k63.5k74.7k140.9k219.5k76.8k142.2k41.3k

Operating expense total

44.3k42.0k34.4k28.7k29.6k39.1k44.2k41.6k26.9k49.0k23.1k91.9k61.8k53.1k93.1k138.0k192.3k101.2k116.0k85.4k102.1k96.1k106.5k97.4k166.1k217.8k276.5k147.8k188.7k82.4k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

4.5k2.4k3.1k317.0371.1k371.0k302.9k136.0k377.3k193.4k

Accounts Receivable

6.5k6.0k119.05.5k8.0k

Prepaid Expenses

18.7k21.5k397.062.1k1.1k1.1k1.1k

Current Assets

379.5k441.4k365.1k137.1k378.4k194.5k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

2.0k6.4k17.5k15.0k5.1k13.9k4.5k2.5k1.7k6.8k10.9k130.7k114.4k163.5k261.0k108.5k89.0k549.2k238.3k386.1k192.1k214.4k110.5k24.1k503.8k289.9k47.9k45.3k44.8k250.4k

Accounts Receivable

4.3k5.4k94.03.9k4.9k6.0k119.01.3k2.2k5.9k7.9k8.0k8.0k8.0k

Prepaid Expenses

9.0k39.8k2.2k731.01.9k18.6k13.6k3.6k1.9k1.9k1.5k880.0637.0167.0154.6k91.4k25.9k142.5k97.7k58.7k62.5k11.1k21.7k45.6k10.6k1.1k1.1k1.1k1.1k

Current Assets

138.0k123.2k172.1k269.2k271.1k180.4k575.1k380.8k483.9k250.8k276.9k121.6k45.9k549.4k300.4k48.9k46.4k45.8k251.4k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(1.2m)(197.1k)(448.6k)(168.5k)(1.3m)(1.5m)(1.5m)(1.2m)(4.2m)(7.6m)

Depreciation and Amortization

1.5k3.0k3.0k3.0k3.0k3.0k

Accounts Payable

(84.2k)28.0k82.6k128.3k(18.2k)(3.7k)(14.8k)49.7k(51.1k)19.4k

Cash From Operating Activities

(396.6k)(149.9k)(105.3k)(229.2k)(574.2k)(820.3k)(605.1k)(453.5k)(850.7k)(881.3k)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(632.7k)(724.1k)(66.4k)(105.8k)(148.6k)(88.8k)(183.5k)(281.4k)(85.3k)(154.7k)(168.7k)(265.1k)(552.2k)(779.7k)(344.9k)(717.8k)(1.1m)(375.4k)(706.8k)(1.0m)(306.6k)(650.9k)(1.0m)(382.4k)(1.2m)(1.7m)(3.2m)(5.4m)(7.1m)(133.1k)

Depreciation and Amortization

750.01.5k2.3k750.01.5k2.3k750.01.5k2.3k750.01.5k2.3k750.01.5k2.3k750.0

Accounts Payable

53.6k(83.9k)(76.0k)(39.5k)(1.5k)12.9k28.9k45.4k(26.3k)(44.5k)(26.1k)75.5k61.6k35.6k44.1k66.7k(5.0k)4.6k(36.3k)(25.0k)(19.2k)(21.5k)(21.9k)(8.2k)(73.5k)(73.5k)(4.3k)4.5k(20.5k)(40.0k)

Cash From Operating Activities

(167.1k)(376.8k)(119.4k)(124.8k)(129.7k)(14.0k)(19.4k)(31.9k)(52.3k)(136.3k)(190.5k)(106.4k)(267.7k)(386.0k)(108.2k)(422.0k)(654.5k)(110.6k)(412.7k)(484.7k)(157.9k)(291.0k)(376.5k)(155.0k)(442.8k)(656.8k)(317.8k)(496.9k)(749.7k)(155.0k)
show all
Show all financial metrics

ProtoKinetix Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

Learn more about our premium products
SecurityScorecard logo

ProtoKinetix Online and Social Media Presence

ProtoKinetix's Trends

Embed Graph

ProtoKinetix Blogs

May 12, 2021

ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions

Marietta, Ohio, May 12, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”)    (OTCQB: PKTX), a clinical-stage biomedical company, today announced its collaboration with IQVIA (NYSE: IQV) to accelerate development of AAGP® (PKX-001) in ocular conditions, specific…
May 04, 2021

ProtoKinetix, AAGP®, and the Journey to Market

Exciting things are happening at ProtoKinetix. Our clinical research is driving forward, we’re forming dynamic new partnerships, and we are poised to witness some incredible developments using our patented anti-aging glycopeptide, AAGP®. Learn more about what’s happening at ProtoKinetix, including A…
April 22, 2021

ProtoKinetix Announces the Resumption of Phase 1b Clinical Trials for the use of AAGP® Treated Islet Cells in the Treatment of Type 1 Diabetes

Marietta, Ohio, April 22, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced Phase I clinical trials of AAGP® (PKX-001) treated islet cells have resumed at the University of Alberta, Edmonton. A…
April 14, 2021

ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat Dry Eye Disease & Ocular Inflammation with AAGP®

Marietta, Ohio, April 14, 2021 ProtoKinetix, Incorporated (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it has engaged a global pharmaceutical company to develop the formulation as a topical ocular drug for the treatment of dry eye disease…
April 07, 2021

Journal of Tissue Engineering and Regenerative Medicine Publishes Peer Reviewed Research Paper Establishing ProtoKinetix AAGP® Enhanced Stem Cell Vision Restoration

Marietta, Ohio, April 7, 2021                                                                                                             ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced the public…
January 22, 2021

Why Dr. Asim Raja believes in the potential of AAGP

Imagine the ability to fully recover from Type 1 diabetes and no longer live your life according to insulin. Imagine a future where we can overcome blindness. AAGP, the glycopeptide developed by ProtoKinetix, has the power to transform regenerative medicine, paving the path toward incredible medical…
Show more

 ProtoKinetix Frequently Asked Questions

  • When was ProtoKinetix founded?

    ProtoKinetix was founded in 1999.

  • Who are ProtoKinetix key executives?

    ProtoKinetix's key executives are Clarence E. Smith, Edward P. McDonough and Michael R. Guzzetta.

  • Who are ProtoKinetix competitors?

    Competitors of ProtoKinetix include International Stem Cell Corporation, Phenomenex and The Biomedical Engineering Society.

  • Where is ProtoKinetix headquarters?

    ProtoKinetix headquarters is located at 412 Mulberry St, Marietta.

  • Where are ProtoKinetix offices?

    ProtoKinetix has an office in Marietta.

  • How many offices does ProtoKinetix have?

    ProtoKinetix has 1 office.